IDEXX Laboratories Inc.

451.90-1.10-0.24%Vol 62.19K1Y Perf 25.94%
Jun 9th, 2023 10:49 DELAYED
BID451.40 ASK452.16
Open451.18 Previous Close453.00
Pre-Market452.14 After-Market-
 -0.86 -0.19%  - -
Target Price
476.88 
Analyst Rating
Strong Buy 1.50
Potential %
5.11 
Finscreener Ranking
     40.96
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
+     35.59
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★★     59.21
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
67.85 
Earnings Rating
Neutral
Market Cap37.51B 
Earnings Date
1st Aug 2023
Alpha0.01 Standard Deviation0.09
Beta1.19 

Today's Price Range

449.39454.72

52W Range

317.06515.79

5 Year PE Ratio Range

34.60105.40

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-3.79%
1 Month
-5.50%
3 Months
-4.08%
6 Months
7.70%
1 Year
25.94%
3 Years
49.50%
5 Years
106.17%
10 Years
980.11%

TickerPriceChg.Chg.%
IDXX451.90-1.1000-0.24
AAPL181.080.51000.28
GOOG123.260.58500.48
MSFT326.931.67000.51
XOM108.270.08090.07
WFC42.380.01000.02
JNJ160.590.32510.20
FB---
GE105.33-0.7400-0.70
JPM141.560.83000.59
ProfitabilityValueIndustryS&P 500US Markets
59.20
26.10
29.40
22.00
19.97
RevenueValueIndustryS&P 500US Markets
2.54B
30.66
12.01
11.57
Earnings HistoryEstimateReportedSurprise %
Q01 20232.382.557.14
Q04 20221.922.056.77
Q03 20222.042.155.39
Q02 20221.541.561.30
Q01 20222.252.270.89
Q04 20211.671.8913.17
Q03 20211.882.037.98
Q02 20212.012.3416.42
Earnings Per EndEstimateRevision %Trend
6/2023 QR2.43-1.62Negative
9/2023 QR2.400.00-
12/2023 FY9.650.73Positive
12/2024 FY11.135.00Positive
Next Report Date1st Aug 2023
Estimated EPS Next Report2.43
Estimates Count7
EPS Growth Next 5 Years %17.30
Volume Overview
Volume62.19K
Shares Outstanding83.00K
Shares Float82.32M
Trades Count2.34K
Dollar Volume28.16M
Avg. Volume383.58K
Avg. Weekly Volume405.38K
Avg. Monthly Volume365.71K
Avg. Quarterly Volume379.66K

IDEXX Laboratories Inc. (NASDAQ: IDXX) stock closed at 453 per share at the end of the most recent trading day (a 0.51% change compared to the prior day closing price) with a volume of 378.80K shares and market capitalization of 37.51B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 9300 people. IDEXX Laboratories Inc. CEO is Jonathan J. Mazelsky.

The one-year performance of IDEXX Laboratories Inc. stock is 25.94%, while year-to-date (YTD) performance is 11.04%. IDXX stock has a five-year performance of 106.17%. Its 52-week range is between 317.06 and 515.79, which gives IDXX stock a 52-week price range ratio of 67.85%

IDEXX Laboratories Inc. currently has a PE ratio of 56.90, a price-to-book (PB) ratio of 77.91, a price-to-sale (PS) ratio of 14.62, a price to cashflow ratio of 65.80, a PEG ratio of 2.32, a ROA of 28.73%, a ROC of 37.61% and a ROE of 120.08%. The company’s profit margin is 19.97%, its EBITDA margin is 29.40%, and its revenue ttm is $2.54 Billion , which makes it $30.66 revenue per share.

Of the last four earnings reports from IDEXX Laboratories Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.43 for the next earnings report. IDEXX Laboratories Inc.’s next earnings report date is 01st Aug 2023.

The consensus rating of Wall Street analysts for IDEXX Laboratories Inc. is Strong Buy (1.5), with a target price of $476.88, which is +5.11% compared to the current price. The earnings rating for IDEXX Laboratories Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

IDEXX Laboratories Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

IDEXX Laboratories Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.64, ATR14 : 11.80, CCI20 : -107.76, Chaikin Money Flow : -0.01, MACD : -7.00, Money Flow Index : 39.09, ROC : -6.84, RSI : 37.44, STOCH (14,3) : 12.64, STOCH RSI : 0.18, UO : 48.48, Williams %R : -87.36), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of IDEXX Laboratories Inc. in the last 12-months were: Brian P. Mckeon (Option Excercise at a value of $0), Daniel M. Junius (Option Excercise at a value of $940 091), Daniel M. Junius (Sold 5 233 shares of value $2 413 318 ), James F. Polewaczyk (Option Excercise at a value of $0), Jonathan J. Mazelsky (Option Excercise at a value of $2 425 980), Jonathan J. Mazelsky (Sold 23 730 shares of value $9 622 228 ), Kathy V. Turner (Option Excercise at a value of $3 290 219), Kathy V. Turner (Sold 17 887 shares of value $7 944 792 ), Lane Michael (Sold 0 shares of value $0 ), M. Anne Szostak (Option Excercise at a value of $320 560), M. Anne Szostak (Sold 740 shares of value $317 127 ), Martin Alexander Smith (Sold 0 shares of value $0 ), Mazelsky Jonathan (Sold 0 shares of value $0 ), Mckeon Brian (Sold 0 shares of value $0 ), Michael J. Lane (Option Excercise at a value of $0), Nimrata Hunt (Option Excercise at a value of $99 970), Polewaczyk James (Sold 0 shares of value $0 ), Sharon E. Underberg (Option Excercise at a value of $0), Tina Hunt (Sold 0 shares of value $0 ), Turner Kathy (Sold 1 000 shares of value $-239 415 ), Turner Kathy (Sold 4 010 shares of value $2 029 413 ), Underberg Sharon (Sold 0 shares of value $0 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (66.67 %)
6 (66.67 %)
6 (60.00 %)
Moderate Buy
1 (11.11 %)
1 (11.11 %)
1 (10.00 %)
Hold
2 (22.22 %)
2 (22.22 %)
3 (30.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.50
Moderate Buy
1.65

IDEXX Laboratories Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

CEO: Jonathan J. Mazelsky

Telephone: +1 207 556-0300

Address: One IDEXX Drive, Westbrook 04092, ME, US

Number of employees: 9 300

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

67%33%

Bearish Bullish

52%48%

Bearish Bullish

61%39%

Bearish Bullish

60%40%

 

News

Stocktwits